Michigan Prostate Cancer Program to Improve Diagnosis and Treatment
Michigan Prostate SPORE 2025-2030
This program develops new tests and targeted treatments for men who have or are at risk for aggressive prostate cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11196271 on NIH RePORTER |
What this research studies
This program brings together laboratory scientists and clinicians to move discoveries into new ways to find and treat aggressive prostate cancer. Work includes validating a urine-based test (MyProstateScore 2.0) to better detect aggressive tumors, studying genetic changes such as CDK12 that affect treatment response, and creating new drug approaches like androgen receptor and CDK12 PROTAC degraders. Some projects enroll patients in clinical trials or use patient tissue and samples, while others use laboratory models to accelerate promising leads toward clinical use. Research is carried out at the University of Michigan with collaborators across academic centers and industry to speed translation into care.
Who could benefit from this research
Good fit: Ideal participants are men with prostate cancer—particularly those with high-risk or metastatic disease, known CDK12 alterations, or men being evaluated for prostate cancer who might use the MPS2 urine test.
Not a fit: People without prostate cancer or those with very low-risk disease who do not need treatment are less likely to benefit directly from this program's interventions.
Why it matters
Potential benefit: If successful, patients could receive more accurate urine-based screening and access to new targeted therapies that reduce the risk of advanced disease and treatment side effects.
How similar studies have performed: Related work from this program has already produced validated tools like the MPS2 urine test and early clinical trial results for CDK12-altered prostate cancer, while many PROTAC therapies remain experimental.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Chinnaiyan, Arul M — University of Michigan at Ann Arbor
- Study coordinator: Chinnaiyan, Arul M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.